Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01175382 · ClinicalTrials.gov registry record · Phase 2
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
A Phase 2 study of Overactive Bladder and Lower Urinary Tract Symptoms, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 3
- Study locations
NCT01175382 is a Phase 2 study of Overactive Bladder and Lower Urinary Tract Symptoms that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 204 participants, roughly in line with the 207-participant average among 45 other Overactive Bladder trials with a reported enrollment target. The trial reports 3 study locations across 3 states.
The verdict
NCT01175382, a Phase 2 study of Overactive Bladder and Lower Urinary Tract Symptoms, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary aim of this project is to evaluate the effectiveness of combined behavioral + drug therapy compared to behavioral treatment alone and drug therapy alone as a way to improve outcomes in the treatment of OAB symptoms in men. We hypothesize that combined therapy will result in better outcomes than either behavioral or drug therapy alone. The second aim is to compare two methods of implementing combined therapy: simultaneously as initial therapy vs. stepped therapy, in which therapies are combined following initial behavioral or drug therapy alone. The third aim is to examine the costs and cost-effectiveness of combined behavioral + drug therapy compared to behavioral or drug therapy alone.
Conditions Studied
Interventions
- BEHAVIORAL Behavioral training
- DRUG Tolterodine + tamsulosin
- OTHER Combined Behavioral + Drug Therapy
Study Locations (3)
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Emory University - Atlanta
Texas
- University of Texas Health Science Center San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01175382
The ClinicalTrials.gov registry entry for NCT01175382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 207-participant average among 45 other Overactive Bladder trials with a reported enrollment target. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 3 interventions - of which Behavioral training is the first listed.
NCT01175382 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT01175382 about?
NCT01175382 is a clinical study titled "Combined Behavioral and Drug Treatment of Overactive Bladder in Men". The primary aim of this project is to evaluate the effectiveness of combined behavioral + drug therapy compared to behavioral treatment alone and drug therapy alone as a way to improve outcomes in the treatment of OAB symptoms in men. We hypothesize that combined therapy will result in better outcom...
What is the current status of trial NCT01175382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2010-07. Estimated completion is 2015-07.
What conditions does trial NCT01175382 study?
This clinical trial studies the following conditions: Overactive Bladder, Lower Urinary Tract Symptoms.
What interventions are being tested in trial NCT01175382?
The interventions under investigation include: Behavioral training (BEHAVIORAL), Tolterodine + tamsulosin (DRUG), Combined Behavioral + Drug Therapy (OTHER).
Who is sponsoring clinical trial NCT01175382?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01175382 being conducted?
This trial has 3 study locations across Alabama, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase
COMPLETED · Phase 2
-
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
COMPLETED · Phase 2
-
Bacterial Genomic Sequencing in Overactive Bladder
COMPLETED · Phase 2
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.